Teladoc Health Statistics
Total Valuation
Teladoc Health has a market cap or net worth of $966.91 million. The enterprise value is $1.23 billion.
Important Dates
The next estimated earnings date is Wednesday, April 29, 2026, after market close.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teladoc Health has 178.40 million shares outstanding. The number of shares has increased by 3.32% in one year.
| Current Share Class | 178.40M |
| Shares Outstanding | 178.40M |
| Shares Change (YoY) | +3.32% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 74.69% |
| Float | 176.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.38 |
| Forward PS | 0.38 |
| PB Ratio | 0.70 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.39 |
| P/OCF Ratio | 3.28 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 37.08, with an EV/FCF ratio of 4.29.
| EV / Earnings | n/a |
| EV / Sales | 0.48 |
| EV / EBITDA | 37.08 |
| EV / EBIT | n/a |
| EV / FCF | 4.29 |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.75.
| Current Ratio | 2.77 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 22.38 |
| Debt / FCF | 3.64 |
| Interest Coverage | -8.29 |
Financial Efficiency
Return on equity (ROE) is -13.93% and return on invested capital (ROIC) is -3.71%.
| Return on Equity (ROE) | -13.93% |
| Return on Assets (ROA) | -3.20% |
| Return on Invested Capital (ROIC) | -3.71% |
| Return on Capital Employed (ROCE) | -6.66% |
| Weighted Average Cost of Capital (WACC) | 8.63% |
| Revenue Per Employee | $451,782 |
| Profits Per Employee | -$35,772 |
| Employee Count | 5,600 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 20.21 |
Taxes
| Income Tax | -35.21M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.55% in the last 52 weeks. The beta is 2.19, so Teladoc Health's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | -35.55% |
| 50-Day Moving Average | 5.41 |
| 200-Day Moving Average | 7.18 |
| Relative Strength Index (RSI) | 52.05 |
| Average Volume (20 Days) | 6,465,557 |
Short Selling Information
The latest short interest is 31.17 million, so 17.47% of the outstanding shares have been sold short.
| Short Interest | 31.17M |
| Short Previous Month | 27.94M |
| Short % of Shares Out | 17.47% |
| Short % of Float | 17.69% |
| Short Ratio (days to cover) | 4.01 |
Income Statement
In the last 12 months, Teladoc Health had revenue of $2.53 billion and -$200.32 million in losses. Loss per share was -$1.14.
| Revenue | 2.53B |
| Gross Profit | 1.76B |
| Operating Income | -163.40M |
| Pretax Income | -235.53M |
| Net Income | -200.32M |
| EBITDA | 33.06M |
| EBIT | -163.40M |
| Loss Per Share | -$1.14 |
Full Income StatementBalance Sheet
The company has $781.08 million in cash and $1.04 billion in debt, with a net cash position of -$259.08 million or -$1.45 per share.
| Cash & Cash Equivalents | 781.08M |
| Total Debt | 1.04B |
| Net Cash | -259.08M |
| Net Cash Per Share | -$1.45 |
| Equity (Book Value) | 1.39B |
| Book Value Per Share | 7.77 |
| Working Capital | 714.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $294.36 million and capital expenditures -$8.89 million, giving a free cash flow of $285.46 million.
| Operating Cash Flow | 294.36M |
| Capital Expenditures | -8.89M |
| Depreciation & Amortization | 196.46M |
| Net Borrowing | -550.63M |
| Free Cash Flow | 285.46M |
| FCF Per Share | $1.60 |
Full Cash Flow StatementMargins
Gross margin is 69.50%, with operating and profit margins of -6.46% and -7.92%.
| Gross Margin | 69.50% |
| Operating Margin | -6.46% |
| Pretax Margin | -9.31% |
| Profit Margin | -7.92% |
| EBITDA Margin | 1.31% |
| EBIT Margin | -6.46% |
| FCF Margin | 11.28% |
Dividends & Yields
Teladoc Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.32% |
| Shareholder Yield | -3.32% |
| Earnings Yield | -20.72% |
| FCF Yield | 29.52% |
Analyst Forecast
The average price target for Teladoc Health is $7.59, which is 40.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.59 |
| Price Target Difference | 40.04% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 3.80% |
| EPS Growth Forecast (5Y) | -20.23% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Teladoc Health has an Altman Z-Score of -6.46 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.46 |
| Piotroski F-Score | 4 |
